ASPE — Aspen Neuroscience Share Price
Last trade - 00:00Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End null | Unit | null | null | null | null | null | nullE | nullE | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Aspen Neuroscience, Inc. is a clinical-stage regenerative medicine biotechnology company. The Company is focused on developing autologous induced-pluripotent stem cell (iPSC)-derived therapies to address neurodegenerative diseases with unmet medical need. Its lead product candidate, sasineprocel, is an investigational single-dose, autologous iPSC-based cell therapy being evaluated for the treatment of Parkinson's disease (PD). It has the potential to be disease-modified by primarily replacing a patient's lost dopaminergic (DA) neurons with dopaminergic neuron precursor cells (DANPCs). The Company is leveraging its proprietary platform to build a diversified pipeline of autologous iPSC-based therapies for the treatment of multiple CNS diseases, with an initial focus on sporadic and genetic PD. The Company is also conducting the open-label Phase 1/2a ASPIRO trial of a single dose of sasineprocel in mid-stage to moderately advanced PD patients.
Directors
- Damien Mcdevitt PRE (59)
- Faheem Hasnain CHM (68)
- Dalen Meeter CFO (48)
- Kim Raineri CTO (53)
- Lisa Johnson-Pratt OTH (62)
- Jeffrey Boerneke GCN (40)
- Thomas Daniel IND (73)
- Douglas Fisher IND (50)
- Cindy Perettie IND (61)
- Caryn Peterson IND (67)
- Andrew Spaventa IND (42)
- Last Annual
- Last Interim
- Incorporated
- May 18th, 2018
- Public Since
- October 30th, 2026
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
Similar to ASPE
4D Molecular Therapeutics
NASDAQ Global Select Market
Aardvark Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
Acadia Pharmaceuticals
NASDAQ Global Select Market
FAQ
As of Today at 24:23 UTC, shares in Aspen Neuroscience are trading at $11.76. This share price information is delayed by 15 minutes.
Shares in Aspen Neuroscience last closed at $11.76 and the price had moved by over the past 365 days. In terms of relative price strength the Aspen Neuroscience share price has matched the S&P500 Index by over the past year.
There is no consensus recommendation for this security.
Find out moreAspen Neuroscience does not currently pay a dividend.
Aspen Neuroscience does not currently pay a dividend.
Aspen Neuroscience does not currently pay a dividend.
To buy shares in Aspen Neuroscience you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $11.76, shares in Aspen Neuroscience had a market capitalisation of .
Here are the trading details for Aspen Neuroscience:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: ASPE
Based on an overall assessment of its quality, value and momentum Aspen Neuroscience is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Aspen Neuroscience. Over the past six months, its share price has matched the S&P500 Index by .
As of the last closing price of $11.76, shares in Aspen Neuroscience were trading -9.18% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Aspen Neuroscience PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $11.76.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Aspen Neuroscience's management team is headed by:
- Damien Mcdevitt - PRE
- Faheem Hasnain - CHM
- Dalen Meeter - CFO
- Kim Raineri - CTO
- Lisa Johnson-Pratt - OTH
- Jeffrey Boerneke - GCN
- Thomas Daniel - IND
- Douglas Fisher - IND
- Cindy Perettie - IND
- Caryn Peterson - IND
- Andrew Spaventa - IND